The drug to suppress the multiplication of coronavirus infection is being developed, but the resulting product will appear later than the antibody-based drug. This is reported by RIA Novosti with reference to Alexander Gintsburg, the director of the Gamaleya National Research Center for Epidemiology and Microbiology.
The Gamaleya Center is developing an antibody-based drug to treat COVID-19 patients, as Gintsburg stated earlier. Clinical trials of the drug should start in January 2022 and be completed within three to four months.
“If you mean drugs that will specifically suppress the reproduction of the virus, we are also working on the development of that type. The existing medications do not suppress the multiplication of the virus well enough to be used to treat severely ill patients,” Alexander Gintsburg told the publication.
He noted that the center is also working on such a series of drugs, but it will take longer for them to appear. The scientist did not give a specific time frame.
As it became known earlier, the Gamaleya Center is planning to create a universal vaccine against rotavirus and influenza.